<p>SH-SY5Y cells were exposed to tunicamycin (500 nm) for 24 h in the absence (medium) or in the presence of PBA (panel A) or PVA (panel B). Cell viability was determined using a LDH release assay and the results are expressed as the means ± SEM. Bars represent the percentage of LDH release over that obtained in untreated cells. **p<0.005; ***p<0.0001 <i>vs</i> tunicamycin treated cells (Medium). Panel C. Immunoblot of procaspase 3 and cleaved caspase 3. A representative image is shown and the bar diagram represents the ratio of cleaved versus total protein (mean ± SEM) in the different conditions and normalizad to the ratio in absence of tunicamycin. <sup>##</sup>p<0.005 <i>vs</i> untreated cells; **p<0.005 <i>vs</i> tunicamycin treated ce...
<p>HK-2 cells were treated with DMSO (VEH), TM (1 µg/ml), 4-PBA alone (1 mM), or TM with 4-PBA for 2...
<p>(A) <i>Left</i>, HeLa cells were treated with DMSO or 2.5 µg/ml of tunicamycin (TM) for 8 h. Tota...
<p>Whole cell lysates from HepG2 cells with treatment with 3 µmol/L tunicamycin (TM) in either the a...
<p>SH-SY5Y cells were treated as described in the Materials and Methods and the expression of GPR78 ...
<p>A) SH-SY5Y cells were treated for 48 h with the indicated concentrations of tunicamycin and cell ...
<p>Cells were treated for 24 h with tunicamycin and with PBA or PVA for the times indicated. The exp...
<p>(A) Representative graph of VSMC cell viability by MTT assay. VSMC were incubated with tunicamyci...
<p><b>A.–B.</b> Cells expressing BS-wt (<b>A.</b>) or BS-5A (<b>B.</b>) were labeled with BgTx-A594 ...
<p><b>A.</b> LLC-PK1 cells were treated with 1 μg/ml tunicamycin (TN) for varying lengths of time as...
<p><b>A, B, and C.</b> LLC-PK1 cells were treated with the ER stress inducer tunicamycin (TN) for 12...
<p><b>A.</b> LLC-PK1 cells were pretreated with 1 μg/ml tunicamycin (TN) for 12 h before a one hour ...
<p>(A) HeLa cells were treated with the indicated concentrations of tunicamycin for 8 hr. The effect...
<p>HK-2 cells were treated with DMSO (VEH), TM (1 µg/ml), TM with 4-PBA (1 mM) or 4-PBA alone for 24...
<p>Cardiomyocytes were treated with 100/ml tunicamycin (Tm) for indicated time (0, 24 h, 48 h, 72 h,...
<p>PBMCs from healthy donors were incubated in the absence (Ctrl) or in the presence (Tm) of 1.25 µg...
<p>HK-2 cells were treated with DMSO (VEH), TM (1 µg/ml), 4-PBA alone (1 mM), or TM with 4-PBA for 2...
<p>(A) <i>Left</i>, HeLa cells were treated with DMSO or 2.5 µg/ml of tunicamycin (TM) for 8 h. Tota...
<p>Whole cell lysates from HepG2 cells with treatment with 3 µmol/L tunicamycin (TM) in either the a...
<p>SH-SY5Y cells were treated as described in the Materials and Methods and the expression of GPR78 ...
<p>A) SH-SY5Y cells were treated for 48 h with the indicated concentrations of tunicamycin and cell ...
<p>Cells were treated for 24 h with tunicamycin and with PBA or PVA for the times indicated. The exp...
<p>(A) Representative graph of VSMC cell viability by MTT assay. VSMC were incubated with tunicamyci...
<p><b>A.–B.</b> Cells expressing BS-wt (<b>A.</b>) or BS-5A (<b>B.</b>) were labeled with BgTx-A594 ...
<p><b>A.</b> LLC-PK1 cells were treated with 1 μg/ml tunicamycin (TN) for varying lengths of time as...
<p><b>A, B, and C.</b> LLC-PK1 cells were treated with the ER stress inducer tunicamycin (TN) for 12...
<p><b>A.</b> LLC-PK1 cells were pretreated with 1 μg/ml tunicamycin (TN) for 12 h before a one hour ...
<p>(A) HeLa cells were treated with the indicated concentrations of tunicamycin for 8 hr. The effect...
<p>HK-2 cells were treated with DMSO (VEH), TM (1 µg/ml), TM with 4-PBA (1 mM) or 4-PBA alone for 24...
<p>Cardiomyocytes were treated with 100/ml tunicamycin (Tm) for indicated time (0, 24 h, 48 h, 72 h,...
<p>PBMCs from healthy donors were incubated in the absence (Ctrl) or in the presence (Tm) of 1.25 µg...
<p>HK-2 cells were treated with DMSO (VEH), TM (1 µg/ml), 4-PBA alone (1 mM), or TM with 4-PBA for 2...
<p>(A) <i>Left</i>, HeLa cells were treated with DMSO or 2.5 µg/ml of tunicamycin (TM) for 8 h. Tota...
<p>Whole cell lysates from HepG2 cells with treatment with 3 µmol/L tunicamycin (TM) in either the a...